326 related articles for article (PubMed ID: 16550930)
1. Myoblast transfer therapy: is there any light at the end of the tunnel?
Mouly V; Aamiri A; Périé S; Mamchaoui K; Barani A; Bigot A; Bouazza B; François V; Furling D; Jacquemin V; Negroni E; Riederer I; Vignaud A; St Guily JL; Butler-Browne GS
Acta Myol; 2005 Oct; 24(2):128-33. PubMed ID: 16550930
[TBL] [Abstract][Full Text] [Related]
2. Initial failure in myoblast transplantation therapy has led the way toward the isolation of muscle stem cells: potential for tissue regeneration.
Urish K; Kanda Y; Huard J
Curr Top Dev Biol; 2005; 68():263-80. PubMed ID: 16125002
[TBL] [Abstract][Full Text] [Related]
3. [The possible place of autologus cell therapy in facioscapulohumeral muscular dystrophy].
Desnuelle C; Sacconi S; Marolleau JP; Larghero J; Vilquin JT
Bull Acad Natl Med; 2005 Apr; 189(4):697-713; discussion 713-4. PubMed ID: 16245686
[TBL] [Abstract][Full Text] [Related]
4. Skeletal Muscle Differentiation on a Chip Shows Human Donor Mesoangioblasts' Efficiency in Restoring Dystrophin in a Duchenne Muscular Dystrophy Model.
Serena E; Zatti S; Zoso A; Lo Verso F; Tedesco FS; Cossu G; Elvassore N
Stem Cells Transl Med; 2016 Dec; 5(12):1676-1683. PubMed ID: 27502519
[TBL] [Abstract][Full Text] [Related]
5. Creation of Dystrophin Expressing Chimeric Cells of Myoblast Origin as a Novel Stem Cell Based Therapy for Duchenne Muscular Dystrophy.
Siemionow M; Cwykiel J; Heydemann A; Garcia-Martinez J; Siemionow K; Szilagyi E
Stem Cell Rev Rep; 2018 Apr; 14(2):189-199. PubMed ID: 29305755
[TBL] [Abstract][Full Text] [Related]
6. Autotransplantation in mdx mice of mdx myoblasts genetically corrected by an HSV-1 amplicon vector.
Bujold M; Caron N; Camiran G; Mukherjee S; Allen PD; Tremblay JP; Wang Y
Cell Transplant; 2002; 11(8):759-67. PubMed ID: 12588108
[TBL] [Abstract][Full Text] [Related]
7. Gene transfer into skeletal muscles by isogenic myoblasts.
Huard J; Acsadi G; Jani A; Massie B; Karpati G
Hum Gene Ther; 1994 Aug; 5(8):949-58. PubMed ID: 7948144
[TBL] [Abstract][Full Text] [Related]
8. Cell-lineage regulated myogenesis for dystrophin replacement: a novel therapeutic approach for treatment of muscular dystrophy.
Kimura E; Han JJ; Li S; Fall B; Ra J; Haraguchi M; Tapscott SJ; Chamberlain JS
Hum Mol Genet; 2008 Aug; 17(16):2507-17. PubMed ID: 18511457
[TBL] [Abstract][Full Text] [Related]
9. Stem cell therapies to treat muscular dystrophy: progress to date.
Meregalli M; Farini A; Parolini D; Maciotta S; Torrente Y
BioDrugs; 2010 Aug; 24(4):237-47. PubMed ID: 20623990
[TBL] [Abstract][Full Text] [Related]
10. Myoblast transfer in the treatment of Duchenne's muscular dystrophy.
Mendell JR; Kissel JT; Amato AA; King W; Signore L; Prior TW; Sahenk Z; Benson S; McAndrew PE; Rice R
N Engl J Med; 1995 Sep; 333(13):832-8. PubMed ID: 7651473
[TBL] [Abstract][Full Text] [Related]
11. [Cell therapy for Duchenne muscular dystrophy].
Zhou C; Zhang C
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Dec; 23(6):659-61. PubMed ID: 17160947
[TBL] [Abstract][Full Text] [Related]
12. [Transplantation of normal or genetically modified myoblasts for the treatment of hereditary or acquired diseases].
Tremblay JP; Vilquin JT
J Soc Biol; 2001; 195(1):29-37. PubMed ID: 11530497
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic potential of PEGylated insulin-like growth factor I for skeletal muscle disease evaluated in two murine models of muscular dystrophy.
Gehrig SM; van der Poel C; Hoeflich A; Naim T; Lynch GS; Metzger F
Growth Horm IGF Res; 2012 Apr; 22(2):69-75. PubMed ID: 22424862
[TBL] [Abstract][Full Text] [Related]
14. Myogenic stem cells from the bone marrow: a therapeutic alternative for muscular dystrophy?
Ferrari G; Mavilio F
Neuromuscul Disord; 2002 Oct; 12 Suppl 1():S7-10. PubMed ID: 12206789
[TBL] [Abstract][Full Text] [Related]
15. Ex vivo gene transfer using adenovirus-mediated full-length dystrophin delivery to dystrophic muscles.
Floyd SS; Clemens PR; Ontell MR; Kochanek S; Day CS; Yang J; Hauschka SD; Balkir L; Morgan J; Moreland MS; Feero GW; Epperly M; Huard J
Gene Ther; 1998 Jan; 5(1):19-30. PubMed ID: 9536261
[TBL] [Abstract][Full Text] [Related]
16. Cell therapy for muscular dystrophies: advances and challenges.
Vilquin JT; Catelain C; Vauchez K
Curr Opin Organ Transplant; 2011 Dec; 16(6):640-9. PubMed ID: 22001714
[TBL] [Abstract][Full Text] [Related]
17. Isolation and characterization of mesoangioblasts from facioscapulohumeral muscular dystrophy muscle biopsies.
Morosetti R; Mirabella M; Gliubizzi C; Broccolini A; Sancricca C; Pescatori M; Gidaro T; Tasca G; Frusciante R; Tonali PA; Cossu G; Ricci E
Stem Cells; 2007 Dec; 25(12):3173-82. PubMed ID: 17761758
[TBL] [Abstract][Full Text] [Related]
18. Rapid death of injected myoblasts in myoblast transfer therapy.
Fan Y; Maley M; Beilharz M; Grounds M
Muscle Nerve; 1996 Jul; 19(7):853-60. PubMed ID: 8965839
[TBL] [Abstract][Full Text] [Related]
19. Ex vivo gene editing of the dystrophin gene in muscle stem cells mediated by peptide nucleic acid single stranded oligodeoxynucleotides induces stable expression of dystrophin in a mouse model for Duchenne muscular dystrophy.
Nik-Ahd F; Bertoni C
Stem Cells; 2014 Jul; 32(7):1817-30. PubMed ID: 24753122
[TBL] [Abstract][Full Text] [Related]
20. Human muscular fetal cells: a potential cell source for muscular therapies.
Hirt-Burri N; de Buys Roessingh AS; Scaletta C; Gerber S; Pioletti DP; Applegate LA; Hohlfeld J
Pediatr Surg Int; 2008 Jan; 24(1):37-47. PubMed ID: 17962961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
